The cost implications of the use of telmisartan or ramipril in patients at high risk for vascular events: the ONTARGET study
暂无分享,去创建一个
S. Yusuf | Á. Avezum | P. Gao | A. Gafni | K. Teo | A. Lamy | Rafael Ferreira | James M Young | Xiaoyin Wang | W. Tong | A. Dans